Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Gains from Sales and Divestitures (2019 - 2025)

Historic Gains from Sales and Divestitures for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to $45072.0.

  • Cyclerion Therapeutics' Gains from Sales and Divestitures fell 2056.26% to $45072.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $45072.0, marking a year-over-year decrease of 2056.26%. This contributed to the annual value of $71763.0 for FY2024, which is 3691.16% down from last year.
  • As of Q3 2025, Cyclerion Therapeutics' Gains from Sales and Divestitures stood at $45072.0, which was down 2056.26% from $30048.0 recorded in Q2 2025.
  • Over the past 5 years, Cyclerion Therapeutics' Gains from Sales and Divestitures peaked at $143774.0 during Q4 2021, and registered a low of $3375.0 during Q2 2023.
  • For the 5-year period, Cyclerion Therapeutics' Gains from Sales and Divestitures averaged around $52982.2, with its median value being $45072.0 (2025).
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first tumbled by 9148.8% in 2023, then skyrocketed by 113600.0% in 2024.
  • Over the past 5 years, Cyclerion Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $143774.0 in 2021, then plummeted by 62.44% to $53999.0 in 2022, then soared by 110.65% to $113750.0 in 2023, then crashed by 36.91% to $71763.0 in 2024, then crashed by 37.19% to $45072.0 in 2025.
  • Its Gains from Sales and Divestitures was $45072.0 in Q3 2025, compared to $30048.0 in Q2 2025 and $15024.0 in Q1 2025.